<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33623">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118519</url>
  </required_header>
  <id_info>
    <org_study_id>KneeUJCTC</org_study_id>
    <nct_id>NCT02118519</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells in Knee Cartilage Injuries</brief_title>
  <official_title>Use of Mesenchymal Stem Cells for the Repair of Articular Cartilage Disorder of Knee Using Intra-articular Injection of Mesenchymal Cells Alone or Mesenchymal Cells With Platelet Lysate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <authority>Jordan: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of autologous repair chondrogenesis to regenerate injured articular cartilage
      using bone marrow mesenchymal stem cells (MSCs) after in vitro expansion under restricted
      culturing conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fourteen patients from both genders, age range 40-68, will be enrolled according to strict
      inclusion and exclusion criteria, divided into two equal groups based upon receiving
      autologous MSCs alone, or MSCs supported by platelet lysate through percutaneous injection.

      The patients are followed by clinical assessment, laboratory investigations as well as
      magnetic resonance imaging (MRI) of the injected knee.

      The investigators hypothesize that the two groups will give satisfactory clinical outcomes,
      but the investigators are looking forward to assessing the best product that will activate
      chondrogenesis and heal cartilaginous injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For every patient tests would be performed repeated at  6, and 12 months post-injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Articular Cartilage Disorder of Knee</condition>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of  patients with advanced articular cartilage injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mesenchymal cells&amp;platelet lysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal Stem Cells</intervention_name>
    <description>Comparison of clinical outcomes of patients injected by mesenchymal  stem cells only with patients injected with mesenchymal  stem cells supported by platelet lysate</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_label>mesenchymal cells&amp;platelet lysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MRI must show moderate/severe articular injury

          -  Serum collagen II  must be above the normal value.

          -  Lesion site: Femoral and Tibial condyles or patella

          -  Admission of steroid , NSAID, pain killers must be stopped before 1 month

        Exclusion Criteria:

          -  Lesion size

          -  PT and PTT not within normal value

          -  Complete blood count ( Hb, PCV, and RBC) not within the normal value

          -  HIV and Hepatitis Antigens (B and C) detection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdallah Awidi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Therapy Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahasen S Najjar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jordan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiba Khalil, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al-Neelain University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatima A Jamali, MSc</last_name>
    <phone>009625355000</phone>
    <phone_ext>23960</phone_ext>
    <email>ftmjamali@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cell Therapy Center, Jordan University Hospital</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima Jamali, MSc.</last_name>
      <phone>009625355000</phone>
      <phone_ext>23960</phone_ext>
      <email>ftmjamali@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dana Hattab, MSc.</last_name>
      <phone>009625355000</phone>
      <phone_ext>23960</phone_ext>
      <email>d.hattab@ju.edu.jo</email>
    </contact_backup>
    <investigator>
      <last_name>Jihad MS AJLOUNI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Osama A Samara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imad Tarawneh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Fatima Jamali</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Bone marrow derived Mesenchymal Stem Cells</keyword>
  <keyword>Knee articular cartilage injury</keyword>
  <keyword>Chondrogenesis</keyword>
  <keyword>orthopedics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cartilage Diseases</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
